Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 19/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3312983 | 0.98 | CXCR4 (0.49) | CXCR4CYP2D6CYP3A4 | |
| SCHEMBL18281428 | 0.81 | CFD (0.43) | CXCR4CYP2D6 | |
| SCHEMBL7839211 | 0.80 | CXCR4 (0.46) | CXCR4CYP2D6CYP3A4 | |
| SCHEMBL23306353 | 0.73 | CYP2D6 (0.38) | CXCR4CYP2D6CYP3A4 | |
| SCHEMBL21743932 | 0.71 | CXCR4 (0.59) | CXCR4CYP2D6CYP3A4 | |
| SCHEMBL21055028 | 0.70 | HDAC1 (0.68) | CXCR4CYP2D6CYP3A4 | |
| SCHEMBL27616527 | 0.70 | ADRA2A (0.46) | CXCR4CYP2D6 | |
| SCHEMBL5575207 | 0.69 | CXCR4 (0.50) | CXCR4CYP2D6CYP3A4 | |
| SCHEMBL3314052 | 0.68 | IGF1R (0.46) | CXCR4CYP2D6 | |
| SCHEMBL30584967 | 0.68 | CXCR4 (0.46) | CXCR4CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317445-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-03-11 | — | — | EP | claimed |
| EP-3735412-A1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | Magenta Therapeutics, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2019136159-A1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | Magenta Therapeutics Inc. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20100105915-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2010-04-29 | — | — | US | disclosed |
| EP-2068868-A2 | COMBINATION THERAPY | Genzyme Corporation (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-2056853-A1 | COMBINATION THERAPY | Genzyme Corporation (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008019371-A1 | COMBINATION THERAPY | GENZYME CORPORATION (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017025-A2 | COMBINATION THERAPY | GENZYME CORPORATION (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-1163238-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056729-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105915-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CXCR4, CCR5, CXCR3 | CXCR4 1/4885CYP2D6 3280/4885CYP3A4 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.